Find therapies in clinical trials near you

Zanidatamab, tucatinib, capecitabine or eribulin mesylate in HER2-positive advanced breast cancer in adults

Zanidatamab, tucatinib, capecitabine or eribulin mesylate in HER2-positive advanced breast cancer in adults

A study testing zanidatamab combined with chemotherapy before surgery in patients with HER2-positive breast cancer

A study testing zanidatamab combined with chemotherapy before surgery in patients with HER2-positive breast cancer

Study of zanidatamab with drug combination for patients with HER2 and PD-L1 positive advanced gastroesophageal cancer

Study of zanidatamab with drug combination for patients with HER2 and PD-L1 positive advanced gastroesophageal cancer

A Study of Zanidatamab for Patients with Previously Treated HER2-Expressing Solid Tumors

A Study of Zanidatamab for Patients with Previously Treated HER2-Expressing Solid Tumors

Study of zanidatamab in adult patients with HER2-positive solid tumors (endometrial, colorectal, head & neck, sarcoma) or HER2-mutant non-small cell lung cancer

Study of zanidatamab in adult patients with HER2-positive solid tumors (endometrial, colorectal, head & neck, sarcoma) or HER2-mutant non-small cell lung cancer

Study on Zanidatamab with Cisplatin and Gemcitabine for Advanced HER2 Positive Biliary Tract Cancer Patients

Study on Zanidatamab and Chemotherapy for Patients with Metastatic HER2-Positive Breast Cancer After Trastuzumab Deruxtecan Treatment

Study on Zanidatamab and Chemotherapy for Patients with Metastatic HER2-Positive Breast Cancer After Trastuzumab Deruxtecan Treatment

Study to Determine the Best Dose of Zongertinib with Trastuzumab Deruxtecan or Trastuzumab Emtansine for Patients with Advanced HER2+ Metastatic Cancer

Study to Determine the Best Dose of Zongertinib with Trastuzumab Deruxtecan or Trastuzumab Emtansine for Patients with Advanced HER2+ Metastatic Cancer

Study on Maintenance Therapy with Cisplatin, Durvalumab, and Trastuzumab for Patients with Advanced Biliary Cancer

Study on Maintenance Therapy with Cisplatin, Durvalumab, and Trastuzumab for Patients with Advanced Biliary Cancer

Perioperative Zanidatamab and Tislelizumab with Chemotherapy for Patients with HER2‑Positive Locally Advanced Operable Gastroesophageal Adenocarcinoma

Perioperative Zanidatamab and Tislelizumab with Chemotherapy for Patients with HER2‑Positive Locally Advanced Operable Gastroesophageal Adenocarcinoma

Study on the Safety and Effects of Zanidatamab, Palbociclib, and Fulvestrant for Patients with Advanced or Metastatic HER2-Positive, HR-Positive Breast Cancer

Study on the Safety and Effects of Zanidatamab, Palbociclib, and Fulvestrant for Patients with Advanced or Metastatic HER2-Positive, HR-Positive Breast Cancer

Study of Zanidatamab and Tislelizumab Combined with Chemotherapy for Patients with Advanced or Metastatic HER2-positive Gastroesophageal Cancer

Study of Zanidatamab and Tislelizumab Combined with Chemotherapy for Patients with Advanced or Metastatic HER2-positive Gastroesophageal Cancer